Bioengineering lactic acid bacteria to secrete the HIV-1 virucide cyanovirin

Journal of Acquired Immune Deficiency Syndromes

Volumn 40, Issue 5, 2005, Pages 512-520

  Pusch, Oliver ^a   Boden, Daniel ^b   Hannify, Sean ^c   Lee, Fred ^d   Tucker, Lynne D ^d   Boyd, Michael R ^e   Wells, Jerry M ^f   Ramratnam, Bharat ^d  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b AARON DIAMOND AIDS RESEARCH CENTER   (United States)

^c INSTITUTE OF FOOD RESEARCH   (United Kingdom)

^d BROWN UNIVERSITY   (United States)

^e UNIVERSITY OF AMSTERDAM   (Netherlands)

^f UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

Cyanovirin; Microbicide; Recombinant lactic acid bacteria

Indexed keywords

ANTIVIRUS AGENT; CYANOVIRIN N; LACTIC ACID;

AFRICA; ANTIVIRAL ACTIVITY; ARTICLE; BIODIVERSITY; BIOENGINEERING; DISEASE ASSOCIATION; DRUG DELIVERY SYSTEM; GENETIC ENGINEERING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IN VIVO STUDY; INFLAMMATION; PRIORITY JOURNAL; SEXUAL TRANSMISSION; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS STRAIN; VIRUS TRANSMISSION; WESTERN BLOTTING;

BACTERIAL PROTEINS; CARRIER PROTEINS; CELL LINE; CELLS, CULTURED; GENETIC ENGINEERING; HIV-1; HUMANS; LACTOBACILLUS PLANTARUM; LACTOCOCCUS LACTIS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; RECOMBINANT PROTEINS;

EID: 27944477727     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.qai.0000187446.76579.d3     Document Type: Article

References (36)

1. Piot P, Feachem RG, Lee JW, et al. Public health. A global response to AIDS: lessons learned, next steps. Science. 2004;304:1909-1910.
2. D'Cruz OJ, Uckun FM. Clinical development of microbicides for the prevention of HIV infection. Curr Pharm Des. 2004;10:315-336.
3. Turpin JA. Considerations and development of topical microbicides to inhibit the sexual transmission of HIV. Expert Opin Investig Drugs. 2002;11:1077-1097.
4. Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis. 2003;37:1102-1106.
5. Cole AM, Lehrer RI. Minidefensins: antimicrobial peptides with activity against HIV-1. Curr Pharm Des. 2003;9:1463-1473.
6. Wild C, Greenwell T, Matthews T. A synthetic peptide from HIV-1 gp41 is a potent inhibitor of virus-mediated cell-cell fusion. AIDS Res Hum Retroviruses. 1993;9:1051-1053.
7. Wild C, Oas T, McDanal C, et al. A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci USA. 1992;89:10537-10541.
8. Mariner JM, McMahon JB, O'Keefe BR, et al. The HIV-inactivating protein, cyanovirin-N, does not block gp120-mediated virus-to-cell binding. Biochem Biophys Res Commun. 1998;248:841-845.
9. Mori T, Boyd MR. Cyanovirin-N, a potent human immunodeficiency virus-inactivating protein, blocks both CD4-dependent and CD4-independent binding of soluble gp120 (sgp120) to target cells, inhibits sCD4-induced binding of sgp120 to cell-associated CXCR4, and dissociates bound sgp120 from target cells. Antimicrob Agents Chemother. 2001;45:664-672.
10. Bewley CA, Otero-Quintero S. The potent anti-HIV protein cyanovirin-N contains two novel carbohydrate binding sites that selectively bind to Man(8) D1D3 and Man(9) with nanomolar affinity: implications for binding to the HIV envelope protein gp120. J Am Chem Soc. 2001;123:3892-3902.
11. Bolmstedt AJ, O'Keefe BR, Shenoy SR, et al. Cyanovirin-N defines a new class of antiviral agent targeting N-linked, high-mannose glycans in an oligosaccharide-specific manner. Mol Pharmacol. 2001;59:949-954.
12. Boyd MR, Gustafson KR, McMahon JB, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother. 1997;41:1521-1530.
13. Shenoy SR, O'Keefe BR, Bolmstedt AJ, et al. Selective interactions of the human immunodeficiency virus-inactivating protein cyanovirin-N with high-mannose oligosaccharides on gp120 and other glycoproteins. J Pharmacol Exp Ther. 2001;297:704-710.
14. Dey B, Lerner DL, Lusso P, et al. Multiple antiviral activities of cyanovirin-N: blocking of human immunodeficiency virus type 1 gp120 interaction with CD4 and coreceptor and inhibition of diverse enveloped viruses. J Virol. 2000;74:4562-4569.
15. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses. 2004;20:11-18.
16. Tsai CC, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses. 2003;19:535-541.
17. Reuter MA, Hanniffy S, Wells JM. Expression and delivery of heterologous antigens using lactic acid bacteria. Methods Mol Med. 2003;87:101-114.
18. Robinson K, Chamberlain LM, Lopez MC, et al. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C. Infect Immun. 2004;72:2753-2761.
19. Steidler L, Hans W, Schotte L, et al. Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science. 2000;289:1352-1355.
20. van Asseldonk M, Rutten G, Oteman M, et al. Cloning of usp45, a gene encoding a secreted protein from Lactococcus lactis subsp. lactis MG1363. Gene. 1990;95:155-160.
21. Gilbert C, Robinson K, Le Page RW, et al. Heterologous expression of an immunogenic pneumococcal type 3 capsular polysaccharide in Lactococcus lactis. Infect Immun. 2000;68:3251-3260.
22. Le Loir Y, Gruss A, Ehrlich SD, et al. A nine-residue synthetic propeptide enhances secretion efficiency of heterologous proteins in Lactococcus lactis. J Bacteriol. 1998;180:1895-1903.
23. Le Loir Y, Nouaille S, Commissaire J, et al. Signal peptide and propeptide optimization for heterologous protein secretion in Lactococcus lactis. Appl Environ Microbiol. 2001;67:4119-4127.
24. Connor RI, Sheridan KE, Ceradini D, et al. Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med. 1997;185:621-628.
25. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Cirr Pharm Des. 2003;9:175-191.
26. Dieye Y, Usai S, Clier F, et al. Design of a protein-targeting system for lactic acid bacteria. J Bacteriol. 2001;183:4157-4166.
27. Antonio MA, Hillier SL. DNA fingerprinting of Lactobacillus crispatus strain CTV-05 by repetitive element sequence-based PCR analysis in a pilot study of vaginal colonization. J Clin Microbiol. 2003;41:1881-1887.
28. Patton DL, Cosgrove Sweeney YT, Antonio MA, et al. Lactobacillus crispatus capsules: single-use safety study in the Macaca nemestrina model. Sex Transm Dis. 2003;30:568-570.
29. Martin HL, Richardson BA, Nyange PM, et al. Vaginal lactobacilli, microbial flora, and risk of human immunodeficiency virus type 1 and sexually transmitted disease acquisition. J Infect Dis. 1999;180:1863-1868.
30. Sewankambo N, Gray RH, Wawer MJ, et al. HIV-1 infection associated with abnormal vaginal flora morphology and bacterial vaginosis. Lancet. 1997;350:546-550.
31. Silvester ME, Dicks LM. Identification of lactic acid bacteria isolated from human vaginal secretions. Antonie Van Leeuwenhoek. 2003;83:117-123.
32. Rabe LK, Hillier SL. Optimization of media for detection of hydrogen peroxide production by Lactobacillus species. J Clin Microbiol. 2003;41:3260-3264.
33. Mbizvo EM, Msuya SE, Stray-Pedersen B, et al. HIV seroprevalence and its associations with the other reproductive tract infections in asymptomatic women in Harare, Zimbabwe. Int J STD AIDS. 2001;12:524-531.
34. van de Wijgert J, Coggins C. Microbicides to prevent heterosexual transmission of HIV: ten years down the road. BETA. 2002;15:23-28.
35. Chang TL, Chang CH, Simpson DA, et al. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two-domain CD4. Proc Natl Acad Sci USA. 2003;100:11672-11677.
36. Kahala M, Palva A. The expression signals of the Lactobacillus brevis slpA gene direct efficient heterologous protein production in lactic acid bacteria. Appl Microbiol Biotechnol. 1999;51:71-78.